Akili Interactive Labs Archives - Medical Design Sourcing

Akili launches its over-the-counter digital ADHD treatment for Android devices

A child uses the EndeavorRx digital therapeutic. [Image courtesy of Akili]Akili (Nasdaq:AKLI) today announced the over-the-counter (OTC) availability of its EndeavorOTC digital ADHD treatment.

Boston-based Akili last week announced a shift toward a non-prescription business model with its OTC offerings. In doing so, the company enacted a workforce reduction of approximately 40%. It included the elimination of the company’s field sales force and market access team.

That move followed a January workforce reduction of 30%, which totaled 46 workers. The company is one of many to slash headcounts as layoffs took medtech by storm recently.

Akili’s launch for EndeavorOTC comes on the Google Play market for popular Android devices. According to a news release, of the estimated 11 million adults with ADHD in the U.S., approximately 40% use Androids. The company believes this marks a crucial step in offering an accessible non-drug treatment option to adults wit…

Akili reduces workforce again in move toward non-prescription models for ADHD treatment

A child uses the EndeavorRx digital therapeutic. [Image courtesy of Akili]Akili (Nasdaq:AKLI) today announced plans for a strategic shift, including a transition from a prescription to a non-prescription business model.

That shift includes a workforce reduction of approximately 40%. It includes the elimination of the company’s field sales force and market access team. That accounts for approximately two-thirds of the reduction. Akili plans to invest a portion of the savings in activities to drive consumer awareness and capital-efficient expansion of its business.

This move follows a January workforce reduction of 30% — totaling 46 workers. The company is one of many to slash headcounts as layoffs took medtech by storm recently. Assuming no major headcount changes since January, another 40% cut for Akili’s remaining staff would total around another 43 employees.

The Boston-based digital medicine developer aims to pursue regulatory approval for ov…

Layoffs in medtech: These companies recently reduced their workforce

[Image courtesy of Nastuh Abootalebi on Unsplash] The workforce reduction trend has swept the economy recently, and unfortunately, the medtech space is not immune to layoffs.

You’ve probably read about the ongoing layoffs sweeping the tech industry, media and more.

For instance, Yahoo, Disney, Zoom and more all reported workforce reductions as companies across industries grapple with economic pressures. Think inflation, supply chain challenges and more.

Medtech has shown some resilience in the present environment. Some major medical device companies released positive earnings. However, others announced headcount reductions, citing macroeconomic headwinds. Others felt the weight of regulatory issues and restructuring efforts.

Here are a few companies across medtech that enacted layoffs over the past several months.

In 3M’s fourth-quarter earnings report, the company announced that it plans to reduce its global manufacturing workforc…

Akili lays off 46 workers

A child uses the EndeavorRx digital therapeutic. [Image courtesy of Akili]Akili announced that its board of directors approved an operating plan for 2023 that includes a 30% workforce reduction.

The Boston-based digital therapeutic developer’s reduction reaches across different areas and functions. In total, 30% of Akili’s workforce amounts to 46 employees. The company communicated the decision to employees on Jan. 12 and expects to complete the reduction by the end of the first quarter.

Get the full story at our sister site, Drug Delivery Business News.

Akili wins CE mark for digital ADHD treatment

Akili Interactive announced today that it received CE Mark approval for its EndeavorRx video game for children with attention deficit hyperactivity disorder (ADHD).

Boston-based Akili’s prescription treatment is delivered through a video game experience as a way to improve attention function as measured by computer-based testing in children between ages 8 and 12 with primarily inattentive or combined-type ADHD.

Despite garnering CE Mark approval, EndeavorRx is not yet available in Europe. However, the company intends to market the system in European Economic Area member countries while its near-term focus remains on its U.S. launch.

Last week, Akili received FDA clearance through the agency’s de novo pathway as a treatment designed to directly target and activate neural systems through the presentation of sensory stimuli and motor challenges to improve cognitive functioning. The company touts it as the first FDA-cleared prescription treatment deliv…

FDA clears video game Rx for kids with ADHD

Akili Interactive announced that it received FDA clearance for its EndeavorRx video game for children with attention deficit hyperactivity disorder (ADHD).

Boston-based Akili’s prescription treatment is delivered through a video game experience to improve attention function as measured by computer-based testing in children between ages 8 and 12 with primarily inattentive or combined-type ADHD.

EndeavorRx received its review through the FDA’s de novo pathway as a treatment designed to directly target and activate neural systems through the presentation of sensory stimuli and motor challenges to improve cognitive functioning, according to a news release.

Clearance was granted based on data from five clinical studies of more than 600 ADHD-diagnosed children. One prospective, randomized, controlled study published in The Lancet Digital Health Journal revealed that EndeavorRx improved objective measures of attention in children with ADHD.

A…